Article
Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.
Journal of gastroenterology - 1 May 2014
Izumi Namiki, Hayashi Norio, Kumada Hiromitsu, Okanoue Takeshi, Tsubouchi Hirohito, Yatsuhashi Hiroshi, Kato Mai, Ki Rito, Komada Yuji, Seto Chiharu, Goto Shoichiro
Abstract excerpt
BACKGROUND: Efficacy of available therapies for patients with HCV who have previously failed treatment is limited. Two Phase III, open-label trials in Japan investigated efficacy and safety of simeprevir and peginterferon-α-2a/ribavirin (PR) combination therapy in treatment-experienced patients with genotype 1 HCV infection. METHODS: In CONCERTO-2, prior non-responders to IFN-based therapy (N = 106) received...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.